

Title (en)  
ANTISENSE OLIGOMERS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE

Title (de)  
ANTISENSE-OLIGOMERE ZUR BEHANDLUNG EINER POLYZYSTISCHEN NIERENERKRANKUNG

Title (fr)  
OLIGOMÈRES ANTISENS POUR LE TRAITEMENT DE LA POLYKYSTOSE RÉNALE

Publication  
**EP 3389782 A4 20190731 (EN)**

Application  
**EP 16876500 A 20161213**

Priority  
• US 201562267252 P 20151214  
• US 2016066417 W 20161213

Abstract (en)  
[origin: WO2017106211A1] Provided herein are methods and compositions for increasing the expression of PC-2, and for treating a subject in need thereof, e.g., a subject with deficient PC-2 protein expression or a subject having Polycystic Kidney Disease (PKD).

IPC 8 full level  
**C12N 15/113** (2010.01); **A61P 13/12** (2006.01); **C12Q 1/68** (2018.01)

CPC (source: EP)  
**A61P 13/12** (2017.12); **C12N 15/111** (2013.01); **C12N 15/1138** (2013.01); **C12Q 1/6883** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/321** (2013.01); **C12N 2320/33** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/156** (2013.01)

Citation (search report)  
• [AP] WO 2016054615 A2 20160407 - COLD SPRING HARBOR LAB [US]  
• [A] JANA KRALOVICOVA ET AL: "Optimal antisense target reducing INS intron 1 retention is adjacent to a parallel G quadruplex", NUCLEIC ACIDS RESEARCH, vol. 42, no. 12, 8 July 2014 (2014-07-08), pages 8161 - 8173, XP055211568, ISSN: 0305-1048, DOI: 10.1093/nar/gku507  
• [A] REYNOLDS DAVID M ET AL: "Aberrant splicing in the PKD2 gene as a cause of polycystic kidney disease", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. 11, November 1999 (1999-11-01), pages 2342 - 2351, XP055598232, ISSN: 1046-6673  
• [A] SAZANI PETER ET AL: "Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 112, no. 4, 1 August 2003 (2003-08-01), pages 481 - 486, XP002506707, ISSN: 0021-9738, DOI: 10.1172/JCI200319547  
• [A] FRIEDMAN KENNETH J ET AL: "Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36193 - 36199, XP002589149, ISSN: 0021-9258, DOI: 10.1074/JBC.274.51.36193  
• [X] DATABASE Geneseq [online] 12 August 2004 (2004-08-12), "Human tissue factor DNA antisense oligonucleotide #33.", XP002792265, retrieved from EBI accession no. GSN:ADO48831 Database accession no. ADO48831 & US 2004102402 A1 20040527 - DOBIE KENNETH W [US]  
• [X] DATABASE EMBL [online] 7 June 2015 (2015-06-07), "Sequence 810960 from Patent EP2850184.", XP002792266, retrieved from EBI accession no. EM\_PAT:JE499093 Database accession no. JE499093 & WO 2013173637 A1 20131121 - RANA THERAPEUTICS INC [US], et al  
• See references of WO 2017106211A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2017106211 A1 20170622**; CA 3005247 A1 20170622; EP 3389782 A1 20181024; EP 3389782 A4 20190731; JP 2018538287 A 20181227; JP 2022046723 A 20220323

DOCDB simple family (application)  
**US 2016066417 W 20161213**; CA 3005247 A 20161213; EP 16876500 A 20161213; JP 2018529219 A 20161213; JP 2022000102 A 20220104